vs
Side-by-side financial comparison of CHEMUNG FINANCIAL CORP (CHMG) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
CHEMUNG FINANCIAL CORP is the larger business by last-quarter revenue ($23.8M vs $12.6M, roughly 1.9× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 32.5%, a 218.2% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 20.3%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 0.2%).
Chemung Canal Trust Company is a New York State chartered trust company based in Elmira, New York. It was founded as a publicly traded bank in 1833.
CHMG vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.8M | $12.6M |
| Net Profit | $7.7M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | 46.1% | — |
| Net Margin | 32.5% | 250.7% |
| Revenue YoY | 20.3% | 24080.8% |
| Net Profit YoY | 30.9% | 250.9% |
| EPS (diluted) | $1.61 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.8M | $12.6M | ||
| Q3 25 | $28.8M | $0 | ||
| Q2 25 | $10.1M | $0 | ||
| Q1 25 | $25.7M | $12.0K | ||
| Q4 24 | $25.9M | $52.0K | ||
| Q3 24 | $24.3M | $65.0K | ||
| Q2 24 | $23.4M | $114.0K | ||
| Q1 24 | $23.7M | $140.0K |
| Q4 25 | $7.7M | $31.5M | ||
| Q3 25 | $7.8M | $-7.4M | ||
| Q2 25 | $-6.5M | $-1.7M | ||
| Q1 25 | $6.0M | $-13.9M | ||
| Q4 24 | $5.9M | — | ||
| Q3 24 | $5.7M | $-17.1M | ||
| Q2 24 | $5.0M | $-17.9M | ||
| Q1 24 | $7.0M | $-12.7M |
| Q4 25 | 46.1% | — | ||
| Q3 25 | 35.0% | — | ||
| Q2 25 | -87.2% | — | ||
| Q1 25 | 29.9% | -122758.3% | ||
| Q4 24 | 29.0% | — | ||
| Q3 24 | 29.8% | -28604.6% | ||
| Q2 24 | 26.8% | -16720.2% | ||
| Q1 24 | 38.3% | -9987.1% |
| Q4 25 | 32.5% | 250.7% | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | -63.9% | — | ||
| Q1 25 | 23.4% | -115550.0% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 23.5% | -26380.0% | ||
| Q2 24 | 21.3% | -15668.4% | ||
| Q1 24 | 29.7% | -9049.3% |
| Q4 25 | $1.61 | $0.56 | ||
| Q3 25 | $1.62 | $-0.13 | ||
| Q2 25 | $-1.35 | $-0.03 | ||
| Q1 25 | $1.26 | $-0.25 | ||
| Q4 24 | $1.24 | — | ||
| Q3 24 | $1.19 | $-0.32 | ||
| Q2 24 | $1.05 | $-0.33 | ||
| Q1 24 | $1.48 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.1M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $254.7M | $59.0M |
| Total Assets | $2.7B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.1M | $40.3M | ||
| Q3 25 | $107.6M | $48.6M | ||
| Q2 25 | $320.1M | $31.2M | ||
| Q1 25 | $53.4M | $48.9M | ||
| Q4 24 | $47.0M | $52.9M | ||
| Q3 24 | $80.4M | $76.3M | ||
| Q2 24 | $70.2M | $63.5M | ||
| Q1 24 | $94.9M | $82.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $99.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $254.7M | $59.0M | ||
| Q3 25 | $245.3M | $26.5M | ||
| Q2 25 | $235.0M | $32.8M | ||
| Q1 25 | $228.3M | $33.8M | ||
| Q4 24 | $215.3M | $46.1M | ||
| Q3 24 | $220.7M | $65.5M | ||
| Q2 24 | $201.2M | $80.5M | ||
| Q1 24 | $197.1M | $96.2M |
| Q4 25 | $2.7B | $68.9M | ||
| Q3 25 | $2.7B | $54.2M | ||
| Q2 25 | $2.9B | $62.1M | ||
| Q1 25 | $2.8B | $77.7M | ||
| Q4 24 | $2.8B | $110.5M | ||
| Q3 24 | $2.8B | $135.2M | ||
| Q2 24 | $2.8B | $149.9M | ||
| Q1 24 | $2.8B | $167.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.5M | $-8.4M |
| Free Cash FlowOCF − Capex | $43.8M | — |
| FCF MarginFCF / Revenue | 183.7% | — |
| Capex IntensityCapex / Revenue | 7.1% | — |
| Cash ConversionOCF / Net Profit | 5.88× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $71.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.5M | $-8.4M | ||
| Q3 25 | $12.2M | $17.4M | ||
| Q2 25 | $9.7M | $-17.7M | ||
| Q1 25 | $7.2M | $-4.0M | ||
| Q4 24 | $29.8M | $-23.4M | ||
| Q3 24 | $9.2M | $12.8M | ||
| Q2 24 | $6.5M | $-18.7M | ||
| Q1 24 | $7.9M | $5.9M |
| Q4 25 | $43.8M | — | ||
| Q3 25 | $11.8M | — | ||
| Q2 25 | $9.4M | — | ||
| Q1 25 | $6.9M | — | ||
| Q4 24 | $26.2M | — | ||
| Q3 24 | $8.6M | — | ||
| Q2 24 | $5.5M | — | ||
| Q1 24 | $7.9M | — |
| Q4 25 | 183.7% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 92.9% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 101.2% | — | ||
| Q3 24 | 35.2% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 33.1% | — |
| Q4 25 | 7.1% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 5.88× | -0.26× | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 5.04× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.30× | — | ||
| Q1 24 | 1.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
